Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
BRIEF-Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer Oct 24 (Reuters) - Amgen Inc AMGN.O:
AMGEN: NEARLY 80% OF PATIENTS ON IMDELLTRA-IMFINZI ALIVE AT ONE YEAR VERSUS 53% WITH DURVALUMAB ALONE & PROGRESSION-FREE SURVIVAL MORE THAN TRIPLED
AMGEN: GRADE 3 OR HIGHER ADVERSE EVENTS OCCURRED IN 20.9% WITH IMDELLTRA PLUS IMFINZI VERSUS 10.8% WITH IMFINZI ALONE
AMGEN: IMDELLTRA IN COMBINATION WITH IMFINZI REDUCED RISK OF DEATH BY 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
AMGEN: SAFETY PROFILE OF IMDELLTRA IN COMBINATION WITH DURVALUMAB CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES
AMGEN: IMDELLTRA PLUS DURVALUMAB EXTENDS MEDIAN OVERALL SURVIVAL TO 21.1 MONTHS VERSUS 12.7 MONTHS WITH DURVALUMAB ALONE
Source text: https://tinyurl.com/ye2yvf5k
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsBrief: AstraZeneca - Perioperative Imfinzi® (Durvalumab) Plus Neoadjuvant Enfortumab Vedotin Reduced Risk Of Recurrence By 49% And Risk Of Death By 42% In Muscle-Invasive Bladder Cancer
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Amgen drug combined with immunotherapy extends survival in lung cancer trial
Brief: AstraZeneca Says ZEGFROVY 200 Mg Administered Orally Once Daily Now Available In US
Factbox: Pharma sector doubles down on AI to slash costs, timelines